Last edition
News about "Personalised Immunotherapy FK-GI101"
Cellipont Bioservices and CellVax Therapeutics Expand Partnership for cGMP Manufacturing of FK-GI101
Cellipont Bioservices and CellVax Therapeutics have expanded their partnership to advance cGMP manufacturing and clinical development of FK-GI101, a personalised immunotherapy targeting gastrointestinal cancers, building on prior collaboration for prostate cancer therapy FK-PC101.
Personalised Immunotherapy FK-GI101 | 30/07/2025 | By Mrinmoy Dey
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members